July 31, 2020
Gmail users: to ensure you're always viewing the entire newsletter, check at the bottom of the email to see if the newsletter has been "clipped" and click "view entire message" if so.
Member/Center Highlights
Case Comprehensive Cancer Center Clinical Partners Again Named Among Nation's Best Hospitals by U.S. News & World Report
The Case Comprehensive Cancer Center's partners in clinical care, Cleveland Clinic and University Hospitals, have once again been recognized in the annual Best Hospitals rankings and ratings. The rankings are designed to assist patients and their doctors in making informed decisions about where to receive care for challenging health conditions or for common elective procedures.

Please see releases from our partner institutions below, who each ranked highly in multiple specialities, where every Top-50 ranking places them in the top 1 percent of hospitals nationally. We are proud to have these institutions as part of our Comprehensive Cancer Center consortium as they work together to further reduce cancer incidence rates, improve treatments and boost survival.
18 Research Teams Receive over $500,000 in Pilot Grants to Study COVID-19
In March, Case Western Reserve University (CWRU) established a COVID-19 Task Force and the Rapid Response COVID-19 Related Pilot Funding Research Opportunity. With support from multiple funding partners across CWRU, the task force awarded over $500,000 in pilot grants to 18 interdisciplinary research teams for the Rapid Response COVID-19 Related Pilot Funding Research Opportunity. Recipients were announced this week, with awards ranging from $20,000 to $40,000 to “support new research initiatives that will make immediate progress toward reducing harm to individuals, groups, and society from the SARS-CoV-2 and COVID-19 pandemic.”

A total of 18 research teams were granted awards, with teams involving faculty from six CWRU schools and colleges, as well as three healthcare systems and three other universities. 10 members of the Case Comprehensive Cancer Center are principal investigators of 9 awarded projects, noted below in bold.

The Rapid Response COVID-19 Related Pilot Funding Research Opportunity awardees, listed by funding source, are:

Case Comprehensive Cancer Center

COVID-19 immune response and burden of disease with and without cancer
Nora Singer, MD and Jonathan Karn, PhD (Co-PI)

Regulation of SARS-CoV-2 receptors using long non-coding RNAs

Center for AIDS Research

Impact on the GI tract from the triple action of HIV, SARS-CoV-2, and opioid use
Alan Levine, PhD (PI)

Regulation of SARS-CoV-2 receptors using long non-coding RNAs

Cleveland Brain Health Initiative

Risk and protective factors for lasting mental health impact of the COVID-19 pandemic
Joel Hughes, PhD (PI)

NSC-based investigation of the role of glia in SARS-CoV-2 neurovirulence
William Lynch (PI)

COVID-19 Pandemic, Social Inequalities, and Mental Health
Megan Holmes, PhD and Robin Rentrope, MPH, MSSA (Co-PI)

Clinical and Translational Science Collaborative

Addressing ethical, social, and regulatory issues in research during the COVID-19 pandemic
Daniel Tisch, PhD, MPH and Aaron Goldenberg, PhD, MPH (Co-PI)

Determining the diagnostic and prognostic value of underlying cutaneous disease and cutaneous eruptions in patients with COVID-19
Anthony Fernandez, MD, PhD and Christine McDonald, PhD (Co-PI)

Neighborhood context of social vulnerability and perceptions of COVID-specific risk and prevention
Elaine Borawski, PhD and Janet McGrath, PhD (Co-PI)

Glycemic control and COVID-19 disease severity among patients with chronic kidney disease
William Bush, PhD (PI)

COVID-19 associated coagulopathy—developing a Point-of-Care Device for Diagnosis

Digestive Health Research Institute

Impact of COVID-19 on alcohol related liver disease

NORD Family Foundation

Detection and capture of SARS-CoV-2 virus and antibodies using CAPTIV
Susann Brady-Kalnay, PhD and Robert Brown, PhD (Co-PI)

Lung immunity after COVID-19
David Canaday, MD and Richard Silver, MD (Co-PI)

Humoral immunity to COVID-19
Christopher King, MD (PI)

Trimeric receptor binding domain of CoV-2 as a multipotential therapeutic agent

Swetland Center for Environmental Health and the Clinical and Translational Science Collaborative (co-sponsor)

Understanding the behaviors of dental aerosol flume and engineering effective capture system for COVID-19 risk mitigation
Bill Yu, PhD and Fabio Piola Rizzante, DDS, MSc, PhD (Co-PI)
NCI Awards $1.15M to CWRU Researchers, Collaborators to Develop New Tool to Guide Oncologists
From The Daily: Case Western Reserve University scientists are developing artificial intelligence (AI) tools to help surgeons and oncologists identify the subtle but critical differences between a recurring tumor and damaged non-cancerous tissue on post-operative MRI scans of certain cancer patients.

The work is being led by Pallavi Tiwari, PhD, and Satish Viswanath, PhD. Both are faculty members in the Case Western Reserve School of Medicine, lead researchers in the Center for Computational Imaging and Personal Diagnostics (CCIPD) at the Case School of Engineering, members of the Case Comprehensive Cancer Center and co-directors of the upcoming Artificial Intelligence in Oncology Symposium.

Tiwari, Viswanath and several collaborators were recently awarded a $1.15 million grant from the National Cancer Institute (NCI)’s Informatics Technology in Cancer Research (ITCR) program to pursue development and dissemination of the AI-informed tools.
Call for Abstracts: Artificial Intelligence in Oncology Symposium
This year's Artificial Intelligence in Oncology Symposium, "Advancing Science and Policy" will feature an awardee session on day two of the conference. All students, postdocs, residents and fellows conducting research in Artificial Intelligence in Oncology are invited to submit abstracts. A committee will review abstracts based on the relationship to cancers and AI, novelty, significance of findings and clarity.

Presentation details
Up to six (6) awardees will be selected to present their work during the virtual symposium for 5 minutes each during a special session on Tuesday, October 20, 2020. These sessions will be pre-recorded from the presenter's home. Remote professional video assistance will be available. Awardees will be notified by Monday, October 5. All other accepted abstracts will be compiled into a document for attendees to access.
Molecular Underpinnings of Colorectal Cancer Disparities
Recording now available!

Hear from Kishore Guda, DVM, PhD on interpreting the mutational signature of African American colorectal cancers in his recent presentation at The V Foundation's Virtual Scientific Conference.

Dr. Guda associate professor of oncology and pathology at the Case Western Reserve University School of Medicine and member of the Case Comprehensive Cancer Center.
Now Live: Searchable Case CCC Membership Directory
We are pleased to announce the launch of a new searchable membership directory, now live on our website. Results will display automatically as filter terms are selected - this includes filtering by research programs and keywords related to areas of study. The directory may also be searched by name by entering an investigator's name and clicking the "search" button with magnifying glass. We hope this improvement will make it easier to find collaborators in your areas of study and access contact details with ease. As always, we appreciate your feedback.

While exploring this new feature, please take the opportunity to review your own web bio and reach out to our communications team to request content updates or submit recent, high-quality headshots if yours is missing or outdated.
Case CCC COVID-19 Resource Hub
As the COVID-19 outbreak progresses, the Case Comprehensive Cancer Center (Case CCC) has centralized COVID-19 related news, resources and funding opportunities for our cancer center community. Content is updated regularly.

To have a cancer-focused resource added to the page, please email  cancer@case.edu.
What's Coming Up
Mark Your Calendar
Early Bird Registration Now Open: Artificial Intelligence in Oncology Symposium 2020
October 19-20, 2020

The second annual Artificial Intelligence in Oncology Symposium will bring together experts in AI and machine learning as well as clinical, industry and federal agency experts in pathology, radiology, drug discovery, and ethics and policy to speak on research developments, regulatory policy, reimbursement and ethics surrounding AI in oncology. For the health and safety of all attendees, this year's symposium will take place virtually.

The symposium will feature four focused sessions, with speakers and panel discussions providing unique perspectives on how AI and machine learning are impacting the major areas of radiology, pathology and -omics in the contexts of precision medicine approaches for characterizing tumors and predicting therapeutic response.

Beyond the science, attendees will be able to network and enjoy a special session highlighting some of the brightest rising stars in the field of AI in oncology, selected from abstract submissions. Submit your abstract by Friday, September 11!

Geraldine McGinty, MD, MBA, FACR will present the symposium plenary, "Fostering a Strong Ecosystem for AI in Medical Imaging." Dr. McGinty is an internationally recognized expert in imaging economics, Chair of the American College of Radiology Board of Chancellors and Chief Strategy and Contracting Officer at Weill Cornell Medicine in New York City.

Additional keynotes in drug discovery, ethics & policy and pathology will be delivered by Russ Altman, MD, PhD of Stanford University, Aashima Gupta, MS of Google, Vinay Prasad, MD, MPH of the University of California, San Francisco, and Yinyin Yuan, PhD of the Institute of Cancer Research, London. Learn more about AIO 2020 speakers.
Additional Upcoming Events
Society of Neuro-Oncology Virtual Conference on Brain Metastases
August 14, 2020
The Society for Neuro-Oncology, in association with the AANS/CNS Section on Tumors, is pleased to announce its virtual Conference on Brain Metastases.

This live event will feature select abstract presentations and invited lectures from the originally scheduled in-person meeting which was set to take place in Toronto. Join the exciting and diverse program on August 14, 2020, from 11am - 4pm (US ET).
NCCN Oncology Policy Virtual Summit
 September 9, 2020
The Summit will explore diverse perspectives related to emerging models to drive down healthcare costs in the United States and their potential impact on access to high-quality cancer care. Major themes of the summit will include an overview of legislative and regulatory efforts to reduce health costs, the current state of value-based payment models, and the impact of these models on providers and patients with cancer. The summit will also explore the unique implications of policies intended to curb costs for rural and other underserved populations.

If you have any questions, please contact Terrell Johnson, Manager, Policy and Advocacy, johnson@nccn.org.
NCCN 2020 Virtual Congress: Hematologic Malignancies
 October 9-10, 2020
Attend this NCCN virtual congress to hear from world-renowned experts in the management of Hematologic Malignancies present the latest treatment advances, updates to the standard of care as recommended in the NCCN Guidelines®, and unique and challenging patient cases.

Co-chaired by Ranjana H. Advani, MD, Stanford Cancer Institute, and Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, this virtual program features presentations and interactive discussions highlighting the treatment options and supportive care for a variety of hematological malignancies.

This program is approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals.
NCCN 2021 Annual Conference: Call for Abstracts
Abstract Deadline: November 11, 2020
NCCN is now accepting abstracts for consideration to be presented during the NCCN 2021 Annual Conference General Poster Session at the Rosen Shingle Creek in Orlando, Florida on Thursday, March 18 and Friday, March 19, 2021. NCCN welcomes original abstracts from investigators in the general oncology community. Submissions will be accepted from academic institutions, teaching and community hospitals, or industry. Both NCCN and non-NCCN institutions may participate.

Research may fall into the general areas below:

  • Clinical Oncology (all phases)
  • Pre-Clinical Oncology
  • Epidemiology/Risks/Prevention
  • Correlative/Genomic
  • Best Practices in Implementation and Use of Clinical Practice Guidelines
  • Quality Improvement
  • Outcomes and Health Services Research
  • Bioinformatics/Information Technology Sciences
Funding Opportunities
Abstract Deadline: August 4, 2020
Award Application Deadline: August 10, 2020

The American Society of Hematology (ASH) Minority Graduate Student Abstract Achievement Award (MGSAAA) provides awardees with a stipend of $1,500 to present their abstract at the ASH annual meeting, where they will hear the latest advances in hematology research and interact with ASH leadership, senior researchers, and fellow minority students and researchers in the field. Those selected will also receive complimentary online subscriptions to Blood and The Hematologist during their remaining graduate school years.
Deadline: Saturday, August 1, 2020
To improve the discovery and advancement of innovative cancer therapeutics, the Case Comprehensive Cancer Center (Case CCC) has initiated a Drug Discovery Initiative and is providing seed funding toward the development of novel cancer therapeutics. To access funding, investigators must participate in the decennial Case CCC Drug Discovery Census. All therapeutic approaches and modalities are welcome! Projects at all stages are welcome! BE COUNTED! The Census is simple to complete and open to all Case CCC Members. Applications will be accepted until August 1, 2020.

Award Description
  • Awards will be milestone-based and project-specific.
  • Our aim is to select a number of projects for seed funding and to continue to support projects that achieve key milestones.
  • Total funds committed to this RFA are $250,000.
  • Note that projects proposing small-molecule approaches will be considered for additional funding opportunities.
The Case Comprehensive Cancer Center is now accepting applications for the Fall 2020 pilot funding opportunities:

  • Available award: $75,000 for one year
  • LOI Deadline: August 10, 2020
  • Full Invited Application Deadline: August 31, 2020

  • Available award: $120,000 for one year
  • Deadline: August 31, 2020

  • Available award: $75,000 for 18 months
  • Deadline: August 31, 2020

  • Available award: $180,000 for 18 months
  • Deadline: August 31, 2020

Questions? Contact casecccpilots@case.edu or Julie DeJager Glavic at 216.368.5780.
AACR
The AACR Clinical Oncology Research (CORE) Training Fellowships Program is designed to provide an effective industry-academic clinical practicum with a unique training opportunity to develop academic clinicians in drug development. Each fellowship provides $100,000 over one year for the fellow to work on site at the facility of one of AACR’s pharmaceutical industry partners. Time to be spent at the industry site over this one-year period can be flexible and is determined upon mutual agreement between the selected fellow, the fellow’s institution, and the industry partner. Indirect costs for up to a maximum of 20% of total direct costs are permitted.

Program Overview
Purpose: This fellowship is designed for early-career clinical scientists who hold a medical degree (MD, DO, or MD/PhD) and are interested in acquiring the knowledge and skills related to clinical trial design and execution from the perspective of the pharmaceutical industry. The fellow will gain real-world experience in clinical development, including drug development, clinical research, clinical trial design, and data analysis.
AACR
The AACR-AstraZeneca Stimulating Therapeutic Advances through Research Training (START) Grants represent an exciting new initiative to encourage and support collaboration. This novel model, which will provide support to postdoctoral or clinical research fellows, combines research experiences in both an academic and industry setting, following a research timeline that will be of greatest benefit to the proposed work.

Each fellowship provides a three-year grant of $225,000 to support the salary and benefits of the fellow while working on a mentored cancer research project. Applicants must plan to spend one year on site at an AstraZeneca facility. One of a number of AstraZeneca’s locations are possible, at the discretion of AstraZeneca. The year at AstraZeneca will be determined on a case-by-case basis, and will be at a time agreed upon by the fellow, the academic supervisor, the AstraZeneca mentor, and AstraZeneca. The research proposed for funding must have direct applicability to cancer with a specific focus on DNA Damage Response (DDR) pathways or epigenetics and may be basic, translational, or clinical in nature.
In The News
Authority Magazine - July 26, 2020
Pallavi Tiwari, PhD was recently interviewed by Authority Magazine where she shared her own journey and perspective of being a woman in STEM. Dr. Tiwari is an assistant professor of biomedical engineering and the Director of the Brain Image Computing (BrIC) laboratory at Case Western Reserve University. She is also a member of the Case CCC's Cancer Imaging Program.
From The NIH
NIH to Invest $58M to Catalyze Data Science and Health Research Innovation in Africa
The National Institutes of Health (NIH) launched a $58 million initiative to advance data science, catalyze innovation and spur health discoveries across Africa. The new five-year program, Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa), will leverage existing data and technologies to develop solutions for the continent's most pressing clinical and public health problems.

Funding Opportunities

In funding announcements , NIH is calling for applications in four areas: an open data science platform and coordinating center; research hubs; research training programs; and ethical, legal and social implications (ELSI) research.

DS-I Africa is intended to encourage partnerships across sectors and engage private, government, nongovernmental organizations and other stakeholders in applications. In addition, interdisciplinary collaborations will bring together data specialists, computer scientists and engineers with biomedical researchers, clinicians and other health experts. The program aims to foster a culture of innovation and entrepreneurship that will result in new software solutions and technologies, produce startups and spin off companies, and partner with governments and businesses to reach scale and impact.

The program is targeting African academic and other non-profit organizations to apply in partnership with private sector, government and other research partners. Applications are due in late 2020 with projects slated to begin in September 2021.

Virtual Symposium Platform available July-November

NIH is hosting a virtual symposium platform with networking tools and online events now through November. These opportunities will communicate the program's key priorities and engage participants in robust scientific discussions on the state of data science in Africa. The platform is designed to encourage networking across disciplines, sectors and geographies to foster collaborations that will produce high quality applications.
Weekly NIH Funding Opportunities and Notices
Notices









Funding Opportunities

New Application Due Dates: October 19 2020, February 17 2021, June 17 2021, October 19 2021, February 17 2022
Renewal, Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022

New Application Due Dates: October 19 2020, February 17 2021, June 17 2021, October 19 2021, February 17 2022
Renewal, Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022

New Application Due Dates: October 19 2020, February 17 2021, June 17 2021, October 19 2021, February 17 2022
Renewal, Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022
COVID-19 Funding Opportunities and Notices
Have something to share?
Use the button below to submit all your news, publications, events, announcements, lab openings and communications requests to the Case CCC Marketing and Communications team! We are here to help.